Last --
Change Today 0.00 / 0.00%
Volume 0.0
ZSAN On Other Exchanges
All times are local (Market data is delayed by at least 15 minutes).

zosano pharma corp (ZSAN) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZOSANO PHARMA CORP (ZSAN)

Related News

No related news articles were found.

zosano pharma corp (ZSAN) Related Businessweek News

No Related Businessweek News Found

zosano pharma corp (ZSAN) Details

Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops drug formulations for the treatment of various indications. The company delivers formulations through the skin using its proprietary transdermal microneedle patch system. Its lead product candidates comprise Weekly ZP-PTH, a proprietary formulation of parathyroid hormone that has completed a Phase I clinical study for the treatment of severe osteoporosis in women; ZP-Glucagon, a proprietary formulation of glucagon, which has completed a Phase I study for the emergency treatment of severe hypoglycemia; and ZP-Triptan, a proprietary formulation of zolmitriptan that has completed preclinical animal studies for the treatment of migraine. Zosano Pharma Corporation has a strategic partnership and license agreement with Novo Nordisk A/S to develop a microneedle patch product to administer semaglutide for the treatment of type 2 diabetes. The company was founded in 2006 and is headquartered in Fremont, California.

32 Employees
Last Reported Date: 07/29/14
Founded in 2006

zosano pharma corp (ZSAN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Chief Operations Officer
Total Annual Compensation: --
Chief Scientific Officer, Executive Vice Pres...
Total Annual Compensation: --
Chief Medical Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

zosano pharma corp (ZSAN) Key Developments

Eli Lilly and Company Enters into Licensing Agreement for Zosano Pharma Corporation's ZP-PTH Product Candidate

Zosano Pharma Corporation and Eli Lilly and Company announced that they have entered into a agreement to develop ZP-PTH, Zosano's proprietary formulation of parathyroid hormone 1-34 (PTH) using Zosano's microneedle patch system for the treatment of osteoporosis patients, globally. Zosano has completed a Phase 2 study of ZP-PTH for the treatment of severe osteoporosis, and plans to conduct Phase 3 development. Under the terms of the agreement, Zosano has granted Lilly a worldwide license to commercialize ZP-PTH. Lilly will make an equity investment of up to $15 million in Zosano concurrent with the consummation of Zosano's initial public offering of equity securities, and additionally make payments upon achievement of certain regulatory and sales milestones totaling up to $300 million for regulatory approvals and up to $125 million for sales milestones. Zosano is also eligible to receive double-digit royalties on sales of products in major markets and will receive reimbursement of all manufacturing costs. Pending successful clinical testing outcomes and regulatory approval of ZP-PTH, Lilly will be responsible for commercialization of the product. Zosano will be responsible for funding and developing the product, including clinical, regulatory and manufacturing scale-up activities. Zosano will also manufacture the product and provide commercial product supply to Lilly.

Zosano Pharma Corporation Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 09:10 AM

Zosano Pharma Corporation Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-12-2014 09:10 AM. Venue: Le Parker Meridien, New York, New York, United States.

Zosano Pharma Corporation Elects Troy Wilson to its Board of Directors

Zosano Pharma Corporation announced the election of Troy Wilson, Ph.D., J.D., to its Board of Directors. Dr. Wilson has more than 15 years of experience in the biotechnology industry and a proven track record of building highly successful biopharmaceutical companies. The appointment increases Zosano Pharma's board membership to six. Dr. Wilson is the President and Chief Executive Officer, co-founder and a member of the board of managers of Avidity NanoMedicines and Wellspring Biosciences.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZSAN:US $0.00 USD 0.00

ZSAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZSAN.
View Industry Companies

Industry Analysis


Industry Average

Valuation ZSAN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOSANO PHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at